Product Code: GVR-4-68040-056-7
Crocin Market Growth & Trends:
The global crocin market size is expected to reach USD 6.79 billion by 2030, expandingat a CAGR of 5.14% from 2023 to 2030, according to a new report by Grand View Research, Inc. The crocin market growth is attributed to the global rise in the prevalence of chronic diseases such as cardiovascular disorders & cancer and the rapidly aging population. According to the Commentary on Chronic Disease Prevention in 2022 published by the National Association of Chronic Disease Directors, nearly 60% of adult Americans have at least one chronic disease.
Oral diseases affect approximately 3.55 bn people, causing discomfort and pain, according to WHO. Paracetamol is commonly used to treat minor to moderate pain, such as headaches, toothaches, backaches, fever, neurological discomfort, and osteoarthritis. As pain levels rise, so does the need for relievers.
The rising incidence of pain is expected to boost the market growth of NSAIDs during the forecast period. According to the CDC in 2019, around 20.4% of the adult population suffered from chronic pain in the U.S. For instance, 1 in 6 people will be over the age of 60 years in the world and by 2050 the population of people aged 60 years and above would double i.e., 2.1 billion, as per the statistics published by WHO.
Paracetamol is the most commonly used analgesic in older people as a means of pain management or mostly to treat lower back or musculoskeletal-related conditions. The rising prevalence of flu and the increased use of OTC products are propelling growth. Migraine is one of the most common diseases, causing headaches and other complications where the usage of Crocin or paracetamol is very high.
Furthermore, key players are engaged in mergers, acquisitions & partnerships, and product launches to strengthen their product portfolios & manufacturing capacities and provide competitive differentiation. For instance, in August 2022, Haleon Group of Companies introduced New Advil PLUS Acetaminophen, a single tablet containing ibuprofen and acetaminophen, in Canada.
Crocin Market Report Highlights:
- Drugs segment dominated the market attributing to the increasing production of paracetamol to be used for relieving pain and fever. Moreover, the increasing use of paracetamol in various formulations in the treatment of pain-related conditions is expected to further propel the growth
- Purity >98% segment held the majority of the crocin market share in 2022. However, the purity <98% segment is expected to show significant growth over the forecast period
- Pain segment dominated the market owing to the increasing usage of paracetamol as an Over-The-Counter (OTC) analgesic with lesser side effects as compared to other painkillers available in the market
- Hospital pharmacy segment dominated the crocin market in 2022. However, the retail pharmacy segment is expected to grow at a significant rate over the forecast period owing to the increasing adoption of OTC products
- North America held the largest share of the market in 2022. The growth in the region can be attributed to the increasing need for pain management drugs among the population in the region
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.1.1 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database:
- 1.3.2 Gvr's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details Of Primary Research
- 1.4 Information Or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach: Commodity Flow Approach
- 1.7 Research Assumptions
- 1.8 List Of Secondary Sources
- 1.9 List Of Abbreviations
- 1.10 Objectives
- 1.10.1 Objective 1
- 1.10.2 Objective 2
- 1.10.3 Objective 3
- 1.10.4 Objective 4
Chapter 2 Executive Summary
- 2.1 Market Snapshot
- 2.2 Segment Snapshot
- 2.3 Segment Snapshot
- 2.4 Competitive Landscape Snapshot
Chapter 3 Crocin Market Variables, Trends, & Scope
- 3.1 Crocin Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Ancillary Market Outlook - Non-Steroidal Anti-Inflammatory Drugs Market
- 3.2 Value Chain Analysis
- 3.2.1 Raw Material Outlook
- 3.2.2 Product Manufacturers
- 3.2.3 Suppliers
- 3.2.4 End-Users
- 3.3 Volume Trend Analysis (2018-2030)
- 3.4 Price Trend Analysis
- 3.4.1 Distribution Of Dispensed Dosage Forms
- 3.5 Regulatory Framework
- 3.6 Market Dynamics
- 3.6.1 Market Driver Impact Analysis
- 3.6.1.1 Rising Prevalence Of Headaches, Flu, And Other Pain-Related Conditions
- 3.6.1.2 Increasing Demand For Pain Management Drugs
- 3.6.1.3 Increased Production Of Paracetamol
- 3.6.2 Market Restraint Analysis
- 3.6.2.1 Side Effects Of Overdosage Of Paracetamol
- 3.6.2.2 Availability Of Alternative Painkillers In The Market
- 3.7 Industry Analysis Tools
- 3.7.1 Porter's Analysis
- 3.7.2 Macroeconomic Analysis
Chapter 4 Crocin Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)
- 4.1 Crocin Market: Application Movement Analysis
- 4.2 Crocin Market Estimates & Forecast, By Application (USD Million)
- 4.2.1 Food
- 4.2.2 Chemical Industry
- 4.2.3 Drug
- 4.2.4 Others
Chapter 5 Crocin Market - Segment Analysis, By Purity, 2018 - 2030 (USD Million)
- 5.1 Crocin Market: Purity Movement Analysis
- 5.2 Crocin Market Estimates & Forecast, By Purity (USD Million)
- 5.2.1 Purity >98%
- 5.2.2 Purity <98%
Chapter 6 Crocin Market - Segment Analysis, by Indication, 2018 - 2030 (USD Million)
- 6.1 Crocin Market: Indication Movement Analysis
- 6.2 Crocin Market Estimates & Forecast, by Indication (USD Million)
- 6.2.1 Pain
- 6.2.2 Pyrexia (Fever)
Chapter 7 Crocin Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)
- 7.1 Crocin Market: Distribution Channel Movement Analysis
- 7.2 Crocin Market Estimates & Forecast, By Distribution Channel (USD Million)
- 7.2.1 Hospital Pharmacy
- 7.2.2 Retail Pharmacy
- 7.2.3 Others
Chapter 8 Crocin Market: Regional Estimates And Trend Analysis, By Application, By Purity, By Indication, And By Distribution Channel
- 8.1 Crocin Market: Regional Outlook
- 8.2 North America
- 8.2.1 North America Crocin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.2.2 U.S.
- 8.2.2.1 Key Country Dynamics
- 8.2.2.2 U.S. Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.2.2.3 Target Disease Incidence
- 8.2.2.4 Target Disease Prevalence
- 8.2.2.5 Competitive Scenario
- 8.2.2.6 Regulatory Framework
- 8.2.2.7 Reimbursement Scenario
- 8.2.3 Canada
- 8.2.3.1 Key Country Dynamics
- 8.2.3.2 Canada Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.2.3.3 Target Disease Incidence
- 8.2.3.4 Competitive Scenario
- 8.2.3.5 Regulatory Framework
- 8.2.3.6 Reimbursement Scenario
- 8.3 Europe
- 8.3.1 Europe Crocin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.3.2 Germany
- 8.3.2.1 Key Country Dynamics
- 8.3.2.2 Germany Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.3.2.3 Target Disease Incidence
- 8.3.2.4 Competitive Scenario
- 8.3.2.5 Regulatory Framework
- 8.3.2.6 Reimbursement Scenario
- 8.3.3 Uk
- 8.3.3.1 Key Country Dynamics
- 8.3.3.2 Uk Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.3.3.3 Target Disease Incidence
- 8.3.3.4 Competitive Scenario
- 8.3.3.5 Regulatory Framework
- 8.3.3.6 Reimbursement Scenario
- 8.3.4 France
- 8.3.4.1 Key Country Dynamics
- 8.3.4.2 France Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.3.4.3 Target Disease Incidence
- 8.3.4.4 Competitive Scenario
- 8.3.4.5 Regulatory Framework
- 8.3.4.6 Reimbursement Scenario
- 8.3.5 Italy
- 8.3.5.1 Key Country Dynamics
- 8.3.5.2 Italy Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.3.5.3 Target Disease Incidence
- 8.3.5.4 Competitive Scenario
- 8.3.5.5 Regulatory Framework
- 8.3.5.6 Reimbursement Scenario
- 8.3.6 Spain
- 8.3.6.1 Key Country Dynamics
- 8.3.6.2 Spain Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.3.6.3 Target Disease Incidence
- 8.3.6.4 Competitive Scenario
- 8.3.6.5 Regulatory Framework
- 8.3.6.6 Reimbursement Scenario
- 8.3.7 Denmark
- 8.3.7.1 Key Country Dynamics
- 8.3.7.2 Denmark Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.3.7.3 Target Disease Incidence
- 8.3.7.4 Competitive Scenario
- 8.3.7.5 Regulatory Framework
- 8.3.7.6 Reimbursement Scenario
- 8.3.8 Sweden
- 8.3.8.1 Key Country Dynamics
- 8.3.8.2 Sweden Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.3.8.3 Target Disease Incidence
- 8.3.8.4 Competitive Scenario
- 8.3.8.5 Regulatory Framework
- 8.3.8.6 Reimbursement Scenario
- 8.3.9 Norway
- 8.3.9.1 Key Country Dynamics
- 8.3.9.2 Norway Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.3.9.3 Target Disease Incidence
- 8.3.9.4 Competitive Scenario
- 8.3.9.5 Regulatory Framework
- 8.3.9.6 Reimbursement Scenario
- 8.4 Asia Pacific
- 8.4.1 Asia Pacific Crocin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4.2 China
- 8.4.2.1 Key Country Dynamics
- 8.4.2.2 China Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.4.2.3 Target Disease Incidence
- 8.4.2.4 Competitive Scenario
- 8.4.2.5 Regulatory Framework
- 8.4.2.6 Reimbursement Scenario
- 8.4.3 India
- 8.4.3.1 Key Country Dynamics
- 8.4.3.2 India Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.4.3.3 Target Disease Incidence
- 8.4.3.4 Competitive Scenario
- 8.4.3.5 Regulatory Framework
- 8.4.3.6 Reimbursement Scenario
- 8.4.4 Japan
- 8.4.4.1 Key Country Dynamics
- 8.4.4.2 Japan Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.4.4.3 Target Disease Incidence
- 8.4.4.4 Competitive Scenario
- 8.4.4.5 Regulatory Framework
- 8.4.4.6 Reimbursement Scenario
- 8.4.5 South Korea
- 8.4.5.1 Key Country Dynamics
- 8.4.5.2 South Korea Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.4.5.3 Target Disease Incidence
- 8.4.5.4 Competitive Scenario
- 8.4.5.5 Regulatory Framework
- 8.4.5.6 Reimbursement Scenario
- 8.4.6 Australia
- 8.4.6.1 Key Country Dynamics
- 8.4.6.2 Australia Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.4.6.3 Target Disease Incidence
- 8.4.6.4 Competitive Scenario
- 8.4.6.5 Regulatory Framework
- 8.4.6.6 Reimbursement Scenario
- 8.4.7 Thailand
- 8.4.7.1 Key Country Dynamics
- 8.4.7.2 Thailand Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.4.7.3 Target Disease Incidence
- 8.4.7.4 Competitive Scenario
- 8.4.7.5 Regulatory Framework
- 8.4.7.6 Reimbursement Scenario
- 8.5 Latin America
- 8.5.1 Latin America Crocin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5.2 Argentina
- 8.5.2.1 Key Country Dynamics
- 8.5.2.2 Argentina Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.5.2.3 Target Disease Incidence
- 8.5.2.4 Competitive Scenario
- 8.5.2.5 Regulatory Framework
- 8.5.2.6 Reimbursement Scenario
- 8.5.3 Brazil
- 8.5.3.1 Key Country Dynamics
- 8.5.3.2 Brazil Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.5.3.3 Target Disease Incidence
- 8.5.3.4 Competitive Scenario
- 8.5.3.5 Regulatory Framework
- 8.5.3.6 Reimbursement Scenario
- 8.5.4 Mexico
- 8.5.4.1 Key Country Dynamics
- 8.5.4.2 Mexico Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.5.4.3 Target Disease Incidence
- 8.5.4.4 Competitive Scenario
- 8.5.4.5 Regulatory Framework
- 8.5.4.6 Reimbursement Scenario
- 8.6 Middle East and Africa
- 8.6.1 Middle East And Africa Crocin Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6.1.1 Target Disease Incidence
- 8.6.1.2 Competitive Scenario
- 8.6.1.3 Regulatory Framework
- 8.6.1.4 Reimbursement Scenario
- 8.6.2 Saudi Arabia
- 8.6.2.1 Key Country Dynamics
- 8.6.2.2 Saudi Arabia Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.6.2.3 Target Disease Incidence
- 8.6.2.4 Competitive Scenario
- 8.6.2.5 Regulatory Framework
- 8.6.2.6 Reimbursement Scenario
- 8.6.3 South Africa
- 8.6.3.1 Key Country Dynamics
- 8.6.3.2 South Africa Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.6.3.3 Target Disease Incidence
- 8.6.3.4 Competitive Scenario
- 8.6.3.5 Regulatory Framework
- 8.6.3.6 Reimbursement Scenario
- 8.6.4 UAE
- 8.6.4.1 Key Country Dynamics
- 8.6.4.2 UAE Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.6.4.3 Target Disease Incidence
- 8.6.4.4 Competitive Scenario
- 8.6.4.5 Regulatory Framework
- 8.6.4.6 REIMBURSEMENT SCENARIO
- 8.6.5 KUWAIT
- 8.6.5.1 Key Country Dynamics
- 8.6.5.2 Kuwait Crocin Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
- 8.6.5.3 Target Disease Incidence
- 8.6.5.4 Competitive Scenario
- 8.6.5.5 Regulatory Framework
- 8.6.5.6 Reimbursement Scenario
Chapter 9 Crocin Market - Competitive Analysis
- 9.1 Recent Developments & Impact Analysis, by Key Market Participants
- 9.1.1 Ansoff Matrix
- 9.1.2 Heat Map Analysis
- 9.1.3 Major Deals and Strategic Alliances Analysis
- 9.1.3.1 Joint Ventures
- 9.1.3.2 Licensing Agreements
- 9.1.3.3 Product Launches
- 9.1.3.1 Conferences and Campaigns
- 9.2 Company Categorization
- 9.2.1 Innovators
- 9.2.2 Market Leaders
- 9.3 Vendor Landscape
- 9.3.1 List of key distributors and channel partners
- 9.3.2 Key customers
- 9.4 Public Companies
- 9.4.1 Competitive Dashboard Analysis
- 9.4.1.1 Market Differentiators
- 9.5 Private Companies
- 9.5.1 List of key emerging companies
- 9.6 Company Profiles
- 9.6.1 TCI Chemicals Pvt. Ltd.
- 9.6.1.1 Company overview
- 9.6.1.2 Financial performance
- 9.6.1.3 Product benchmarking
- 9.6.1.4 Strategic Initiatives
- 9.6.2 Merck KGaA
- 9.6.2.1 Company overview
- 9.6.2.2 Financial performance
- 9.6.2.3 Product benchmarking
- 9.6.2.4 Strategic Initiatives
- 9.6.3 GSK plc.
- 9.6.3.1 Company overview
- 9.6.3.2 Financial performance
- 9.6.3.3 Product benchmarking
- 9.6.3.4 Strategic Initiatives
- 9.6.4 Cayman Chemical
- 9.6.4.1 Company overview
- 9.6.4.2 Financial performance
- 9.6.4.3 Product benchmarking
- 9.6.4.4 Strategic Initiatives
- 9.6.5 APExBIO Technology
- 9.6.5.1 Company overview
- 9.6.5.2 Financial performance
- 9.6.5.3 Product benchmarking
- 9.6.5.4 Strategic Initiatives
- 9.6.6 Wilshire Technologies
- 9.6.6.1 Company overview
- 9.6.6.2 Financial performance
- 9.6.6.3 Product benchmarking
- 9.6.6.4 Strategic Initiatives
- 9.6.7 Biosynth
- 9.6.7.1 Company overview
- 9.6.7.2 Financial performance
- 9.6.7.3 Product benchmarking
- 9.6.7.4 Strategic initiatives
- 9.6.8 Cipla, Inc.
- 9.6.8.1 Company overview
- 9.6.8.2 Financial performance
- 9.6.8.3 Product benchmarking
- 9.6.8.4 Strategic initiatives
- 9.6.9 Novartis AG
- 9.6.9.1 Company overview
- 9.6.9.2 Financial performance
- 9.6.9.3 Product benchmarking
- 9.6.9.4 Strategic initiatives
- 9.6.10 Sanofi
- 9.6.10.1 Company overview
- 9.6.10.2 Financial performance
- 9.6.10.3 Product benchmarking
- 9.6.10.4 Strategic initiatives
- 9.6.11 Aurobindo Pharma
- 9.6.11.1 Company overview
- 9.6.11.2 Financial performance
- 9.6.11.3 Product benchmarking
- 9.6.11.4 Strategic initiatives
- 9.6.12 Teva Pharmaceutical Industries Ltd.
- 9.6.12.1 Company overview
- 9.6.12.2 Financial performance
- 9.6.12.3 Product benchmarking
- 9.6.12.4 Strategic initiatives
- 9.6.13 Mallinckrodt
- 9.6.13.1 Company overview
- 9.6.13.2 Financial performance
- 9.6.13.3 Product benchmarking
- 9.6.13.4 Strategic initiatives